Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|November 1, 2012
FDA Approves Single REMS for Mycophenolate Class of Drugs
FDA approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for all mycophenolate-containing prescription drugs at the end of September.
Advertisement
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Advertisement
Advertisement